Antihypertensive Medications and Change in Stages of Chronic Kidney Disease
Table 2
Adjusted## odds ratios (95% CI) for advanced (3, 4, and 5) versus early (1 and 2) stages of CKD by use of each class of medication.
Model: class
1999–2004 odds ratio (95% CI)
2005–2008 odds ratio (95% CI)
2009–2012 odds ratio (95% CI)
ACE I
Overall
1.08 (0.69–1.70)
0.85 (0.63–1.14)
0.67 (0.43–1.04)
0.1574
Polytherapy
0.93 (0.57–1.52)
0.83 (0.60–1.15)
0.74 (0.46–1.20)
0.5417
Monotherapy
1.59 (0.91–2.80)
1.06 (0.65–1.73)
0.70 (0.33–1.48)
0.0713
ARB
Overall
0.67 (0.36–1.23)
1.30 (0.87–1.94)
2.52 (1.32–4.80)
0.0069
Polytherapy
0.55 (0.29–1.03)
1.20 (0.80–1.80)
2.63 (1.37–5.07)
0.0023
Monotherapy
1.97 (0.63–6.18)
1.66 (0.83–3.31)
1.39 (0.56–3.46)
0.6575
BB
Overall
1.05 (0.71–1.57)
1.19 (0.87–1.61)
1.34 (0.82–2.17)
0.4637
Polytherapy
1.05 (0.67–1.65)
1.23 (0.89–1.69)
1.43 (0.91–2.27)
0.3490
Monotherapy
0.98 (0.43–2.28)
0.88 (0.47–1.64)
0.78 (0.29–2.13)
0.7414
CCB
Overall
1.28 (0.85–1.93)
1.17 (0.86–1.59)
1.08 (0.67–1.72)
0.5953
Polytherapy
1.14 (0.73–1.78)
1.22 (0.88–1.70)
1.31 (0.77–2.22)
0.7036
Monotherapy
1.24 (0.63–2.46)
0.78 (0.45–1.36)
0.49 (0.24–1.02)
0.0359
DIU
Overall
1.27 (0.81–2.00)
1.49 (1.13–1.98)
1.76 (1.16–2.67)
0.3344
Polytherapy
1.37 (0.88–2.13)
1.65 (1.24–2.20)
1.99 (1.29–3.06)
0.2665
Monotherapy
0.31 (0.11–0.91)
0.30 (0.12–0.73)
0.29 (0.06–1.29)
0.9288
Number of Classes med >1 (polytherapy) versus = 1 (monotherapy)
Combination
1.12 (0.74–1.70)
1.73 (1.30–2.30)
2.67 (1.74–4.09)
0.0063
= Angiotensin Converting Enzyme Inhibitors; ARB = Angiotensin Receptor Blockers; BB = β-blockers; CCB = Calcium Channel Blockers; DIU = Diuretics; #PROC SURVEYLOGISTIC was used to test the trend; ##Adjusted for: age, gender, race, body mass index, smoking status diabetes, and albuminuria; NOTE. Significant associations and -values with level of significance are presented in bold.
